Marketed as Exdensur, the ultra-long-acting biologic is the first of its kind, requiring only two injections per year to ...

An asthma treatment that only requires patients to have two jabs a year to prevent life-threatening attacks will be available ...

The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for ...

The U.S. Food and Drug Administration has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe ...

WASHINGTON - The Food and Drug Administration has approved Exdensur as an add-on maintenance treatment for patients aged 12 ...

The FDA approved depemokimab as an add-on maintenance treatment in patients aged at least 12 years with severe asthma and an ...

The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...

An injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further treatment by 30%. The findings, published today in ...

Indiana University School of Medicine researchers are taking a closer look at how young patients respond to biologic ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

A new study published in Respiratory Medicine offers hope for a long-term treatment of asthma by directly targeting the structural changes that occur in the airway and lungs. Unlike current drugs that ...